Overview: 21-Hydroxylase Deficiency Steroid Panel
Introduction: The 21-Hydroxylase Deficiency Steroid Panel is a diagnostic tool designed to screen for 21-hydroxylase deficiency using serum samples. In India, 21-OH deficiency is the most common CAH form (~90 percent), presenting with salt-wasting crisis in neonates or virilization/precocious puberty in children. High morbidity from under-testing in rural/low-SES newborns with vomiting, dehydration, or ambiguous genitalia, limited endocrine labs, delayed glucocorticoid/mineralocorticoid replacement leading to shock or death. Per pediatric endocrinology practices aligned with ICMR and Indian Society for Pediatric and Adolescent Endocrinology guidelines, the test employs spectrophotometry for 17-OHP, cortisol, ACTH, androstenedione, and testosterone over 1-2 days with high accuracy, valuable for confirming diagnosis (elevated 17-OHP >1000 ng/dL diagnostic) and monitoring treatment. This diagnostic falls under endocrine screening and targets neonates/infants with crisis or virilization, addressing accurate detection to guide life-saving hormone replacement. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early CAH confirmation and reducing neonatal mortality. Its serum-based approach ensures reliable steroid profiling.
Other Names: 21-OH Def Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/endocrinology, compliant with 2025 standards.
Historical Milestone: 17-OHP screening standard in CAH; in India, key in NBS pilots.
Purpose: The test assesses 5 parameters including 17-OHP to guide 21-OH deficiency screening, detect enzyme defect, inform replacement.
Test Parameters: 1. 17-OHP, 2. Cortisol, 3. ACTH, 4. Androstenedione, 5. Testosterone.
Pretest Condition: Fasting 10-12 hours recommended (if feasible); patients should have CAH suspicion.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve steroid integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients/parents should provide details on neonatal crisis, virilization.
Consent: Written informed consent (parental) is required, detailing the test's purpose, potential risks of undetected CAH including shock, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Markedly elevated 17-OHP + low cortisol indicates 21-OH deficiency, necessitating specialist input.
Specialist Consultation: Pediatric endocrinologists should be consulted for management.
Additional Supporting Tests: ACTH stimulation, genetic testing for confirmation.
Test Limitations: Stress elevation in non-classic; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, Endocrine Studies India 2023.
